Healthcare
Live Price
Offline$10.42
+7.87% today
1Y Change
+156.23%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
4D Molecular Therapeutics, Inc. (FDMT) is a Healthcare stock with a market cap of $540.00M and listed on NASDAQ. The stock last traded around $10.42 and up 156.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +230194.6%, EPS growth of +18.8%, a dividend yield of 0.0%. What stands out right now is revenue +230194.6%, EPS +18.8%, free cash flow +21.2% with operating margin -187.2% and ROIC -30.2%. Valuation sits in the middle of the pack at price/sales 6.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines FDMT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
FDMT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
FDMT Max Drawdown
-41.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for FDMT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$18.0M
+476.5% YoY
FY Net Income
-$71.3M
+33.7% YoY
Free Cash Flow
-$78.2M
+20.3% YoY
Revenue Growth
+230194.6%
EPS Growth
+18.8%
Gross Margin
-14.0%
Net Margin
-164.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 85M | 37K | 21M | 3M | 18M |
| Gross Profit | 78M | 37K | -76M | -77M | -43M |
| Operating Income | -160M | -188M | -113M | -110M | -71M |
| EBITDA | -152M | -181M | -109M | -108M | -70M |
| Net Income | -140M | -161M | -101M | -107M | -71M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60M | 149M | 249M | 52M | 153M |
| Total Assets | 567M | 560M | 340M | 262M | 353M |
| Total Liabilities | 61M | 50M | 32M | 31M | 34M |
| Shareholder Equity | 506M | 511M | 308M | 231M | 319M |
| Total Debt | 21M | 25M | 15M | 16M | 16M |
| Net Debt | -39M | -125M | -234M | -36M | -137M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
69M
+20.2% YoY
Capital Expenditures
9M
+21.0% YoY
Free Cash Flow
78M
+20.3% YoY
Key ratios
Gross Margin
-14.0%
Operating Margin
-187.2%
Net Margin
-164.4%
ROE
-31.7%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.